Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFL-PDT vs MAL-PDT for Bowen's Disease
NCT03320447Phase 1Completed
- Sponsor
- Dong-A University
- Start
- Oct 2011
- Primary completion
- Oct 2016
- Modality
- Light/Condition-Responsive Prodrugs
01
Overview
Phase 1, randomised, open-label trial of methyl aminolevulinate in squamous cell carcinoma in situ (SCCIS) (2 arms), sponsored by Dong-A University. Primary endpoints: Short-term Complete Response Rate at 3 months, Long-term Complete Response Rate at 60 months and 1 more. Started Oct 2011; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
squamous cell carcinoma in situ (SCCIS)
Beyond the preview
Go deeper on NCT03320447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320447.